Two clinical trials of an intraocular @entity134 delivery system for XXXX surgery.

@entity1 @entity32 @entity231 @entity619 @entity134 @entity230
PURPOSE: To determine the safety and efficacy of an intraocular @entity619 drug delivery system (Surodex) in the treatment of @entity32 following @entity231 surgery. METHODS: Surodex is a biodegradable polymer that releases @entity619 for 7 to 10 days after placement in the anterior segment. Study 1 was a prospective, randomized, double-masked Phase II clinical trial of 90 @entity231 surgical @entity1 that compared treatment with Surodex to treatment with a placebo drug delivery system and to no anti-inflammatory drug treatment at all. Study 2 was a separate prospective, randomized, double-masked study of 60 @entity231 surgical @entity1 that compared treatment with Surodex to topical @entity619 (eye drop) therapy. RESULTS: In the first study, Surodex was superior to placebo in suppressing postsurgical @entity32 throughout the 60-day postoperative period, as judged by masked-evaluator, slit-lamp grading of cell and flare. The differences were statistically significant from postoperative day 3 through postoperative week 3. The majority of Surodex @entity1 did not require topical @entity134 by 2 weeks after surgery (93%) or by 2 months after surgery (88%). In the second study, Kowa laser flare meter readings were lower in Surodex @entity1 throughout the 90-day postoperative period. The results were statistically significant at 4, 8, and 15 days following surgery. There were no significant adverse complications of Surodex in either study. CONCLUSION: Surodex was safe and effective in suppressing postcataract surgery @entity32 and appears to be a promising alternative to topical @entity230 .
